Glaukos IPO Info
Company Name: Glaukos
Stock Symbol: GKOS
Exchange: NYSE
Status: Priced
IPO Date: 6/25/2015
IPO Price:
18.00 (
37.17%)
Underwriters
J.P. Morgan, BofA Merrill Lynch, Goldman, Sachs & Co., William Blair, Cantor Fitzgerald & Co.
Amount of Offering: N/A
Number of Shares Offered: 5.358 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
We are an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world's leading causes of blindness. We have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. We launched the iStent, our first MIGS device, in the United States in July 2012 and we are leveraging our platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. We believe the iStent is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide.
News Headlines
